阿替利珠单抗联合贝伐珠单抗治疗后肝细胞癌主门静脉累及、右心室侵犯及肺转移进展 **解析**： - 原句中的“Pseudoprogression”是一种影像学表现，指在治疗过程中肿瘤体积暂时增大或出现新的病灶，但实际上是肿瘤坏死或炎症反应所致，并非真正的肿瘤进展。 - “Hepatocellular Carcinoma”指肝细胞癌，是一种常见的肝癌类型。 - “Atezolizumab”和“Bevacizumab”是两种药物的商品名，分别为阿替利珠单抗和贝伐珠单抗，都是用于治疗癌症的靶向药物。 - “Portal Vein”指门静脉，是肝脏的主要血管之一，负责将来自胃肠道的血液输送到肝脏进行处理。 - “Right Ventricular Invasion”指右心室侵犯，是癌细胞侵犯右心室的一种表现。 - “Exacerbation of Lung Metastases”指肺转移进展，是指肺癌患者的肺转移病灶数量或大小增加。
Hepatocellular Carcinoma Pseudoprogression Involving the Main Portal Vein, Right Ventricular Invasion, and Exacerbation of Lung Metastases in a Patient on Atezolizumab Plus Bevacizumab.
机构信息
Department of Gastroenterology and Hepatology, Mie University Graduate School of Medicine, Japan.
出版信息
Intern Med. 2023 Feb 15;62(4):539-543. doi: 10.2169/internalmedicine.9701-22. Epub 2022 Jun 21.
A 70-year-old man was diagnosed with hepatocellular carcinoma (HCC) with portal vein invasion and lung metastases, for which atezolizumab plus bevacizumab (ATZ/BEV) was initiated. After two months, computed tomography revealed tumor growth accompanied by ascites, right ventricular invasion, exacerbation of the lung metastases, and main portal vein invasion. However, continuation of ATZ/BEV caused remarkable size reductions in all lesions, finally resulting in the disappearance of the vascular invasion and lung metastases after nine cycles of treatment. The tumor growth was considered to reflect pseudoprogression, which is difficult to distinguish from hyperprogression. We herein report a remarkable HCC case of pseudoprogression on ATZ/BEV.
一位 70 岁男性被诊断患有肝细胞癌（HCC）伴门静脉侵犯和肺转移，开始使用阿替利珠单抗联合贝伐珠单抗（ATZ/BEV）治疗。两个月后，计算机断层扫描显示肿瘤生长伴有腹水、右心室侵犯、肺转移恶化和主门静脉侵犯。然而，继续使用 ATZ/BEV 导致所有病变明显缩小，最终在九个周期的治疗后血管侵犯和肺转移消失。肿瘤生长被认为是假进展，这很难与超进展区分。我们在此报告一例在 ATZ/BEV 治疗下显著的 HCC 假进展病例。
Zotero 插件